Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Hang Phan
CONTACT
Lead
Dana-Farber Cancer Institute
With
The study consists of two parts: Phase 1b: A safety lead-in using a 3+3 dose escalation design to determine the recommended dose of roginolisib (40 mg or 80 mg QD) in combination with obinutuzumab. After 6 months of combination therapy, venetoclax is added for 6-12 months. DLTs are assessed at the end of cycle 2. Phase 2: Dose expansion at the recommended phase 2 dose. Participants receive obinutuzumab and roginolisib for 6 months, followed by venetoclax and roginolisib for an additional 6 months. Participants who do not achieve uMRD after 12 months may continue therapy for another 6 months. All participants will receive roginolisib orally once daily, obinutuzumab intravenously as per label for 6 cycles, and venetoclax orally as per label starting at cycle 7 with standard ramp-up. The primary endpoint is the rate of objective response with uMRD in bone marrow at the end of one year of combination therapy. Up to 40 patients will be enrolled over 36 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
